	2012 Mar 31	C 2013 Mar 31	C 2014 Mar 31	2015 Mar 31	R 2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR
Total Revenue	7,115	8,279	10,173	11,345	13,595	14,394	15,156	16,362	17,132	19,160	21,763	22,753	25,774	27,548	28,163
Cost of Operating Revenue	3,582	3,829	4,805	5,315	6,590	7,014	7,303	7,792	8,034	9,329	10,549	10,332	10,896	11,153	11,951
Gross Profit	3,533	4,450	5,368	6,030	7,005	7,380	7,853	8,571	9,098	9,830	11,215	12,421	14,878	16,394	16,211
Gross Margin	49.7	53.7	52.8	53.2	51.5	51.3	51.8	52.4	53.1	51.3	51.5	54.6	57.7	59.5	57.6
Total Operating Expenses	5,637	6,395	8,399	9,687	11,869	12,739	13,279	14,362	15,026	15,910	18,201	18,745	20,425	21,415	23,321
Operating Profit	1,478	1,884	1,774	1,658	1,725	1,656	1,877	2,000	2,106	3,249	3,563	4,008	5,349	6,132	4,841
Operating Margin	20.8	22.8	17.4	14.6	12.7	11.5	12.4	12.2	12.3	17.0	16.4	17.6	20.8	22.3	17.2
Financing Income/(Expense) - Net	6	155	69	-44	-45	10	87	153	100	-14	72	118	285	193	-2
Profit before Taxes	1,448	2,095	1,880	1,654	1,727	1,222	1,669	2,079	2,178	3,290	3,493	4,038	5,702	6,821	5,224
Income Taxes	307	544	463	400	332	180	250	570	631	889	934	1,203	1,547	1,530	1,354
Profit after Tax	1,144	1,545	1,388	1,181	1,360	1,006	1,411	1,528	1,547	2,405	2,517	2,802	4,122	5,273	3,879
PAT Margin	16.1	18.7	13.6	10.4	10.0	7.0	9.3	9.3	9.0	12.6	11.6	12.3	16.0	19.1	13.8
EPS - Basic - ex Extraordinary Items	14.25	19.24	17.29	14.71	16.93	12.52	17.53	18.97	19.19	29.82	31.20	34.72	51.05	65.29	48.03
EPS - Diluted - ex Extraordinary Items	14.25	19.24	17.27	14.66	16.89	12.50	17.50	18.93	19.16	29.79	31.17	34.69	51.05	65.24	48.00
EBIT	1,478	1,884	1,774	1,658	1,725	1,656	1,877	2,000	2,106	3,249	3,563	4,008	5,349	6,132	4,841
EBITDA	1,790	2,214	2,147	2,163	2,480	2,527	2,826	3,096	3,203	4,250	4,551	5,026	6,289	7,126	5,924
EBITDA Margin	25.2	26.7	21.1	19.1	18.2	17.6	18.6	18.9	18.7	22.2	20.9	22.1	24.4	25.9	21.0

Balance Sheet

Abridged

Understanding Balance Sheet

Cipla Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	R 2012 Mar 31	R 2013 Mar 31	C 2014 Mar 31	R 2015 Mar 31	R 2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Source:	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR
Total Current Assets	5,057	6,784	5,652	7,558	8,841	8,805	10,814	12,427	11,706	13,210	14,728	17,275	19,441	23,289	24,146
Long-Term Investments	97	105	116	128	160	125	148	256	344	317	694	542	1,037	782	1,510
Property Plant & Equipment - Net	3,587	3,977	4,350	4,649	5,346	5,728	5,828	5,445	5,549	5,527	5,547	5,680	5,933	6,475	7,626
Total Non-Current Assets	4,293	4,875	7,751	8,089	12,287	12,232	12,046	11,537	11,956	11,942	12,374	12,188	13,276	14,099	18,350
Total Assets	9,350	11,659	13,403	15,647	21,128	21,037	22,861	23,963	23,663	25,152	27,101	29,463	32,718	37,387	42,496
Total Current Liabilities	1,413	2,278	2,564	3,762	7,776	3,374	3,832	3,772	4,393	4,592	4,913	5,110	5,246	5,484	7,014
Long Term Debt	3	1	318	309	222	3,645	3,662	3,830	2,552	1,401	575	209	225	252	382
Total Non-Current Liabilities	298	362	740	896	1,486	4,681	4,431	4,838	3,203	1,967	1,064	640	670	614	962
Total Liabilities	1,711	2,640	3,303	4,658	9,262	8,055	8,263	8,609	7,596	6,559	5,977	5,750	5,915	6,098	7,976
Total Shareholders' Equity	7,639	9,019	10,050	10,658	11,516	12,544	14,245	15,022	15,772	18,334	20,849	23,408	26,706	31,193	34,432
Minority Interest	-	-	50	332	350	438	352	332	294	259	276	306	96	96	88
Total Equity	7,639	9,019	10,100	10,989	11,866	12,982	14,597	15,354	16,066	18,593	21,124	23,714	26,802	31,289	34,520
Total Liabilities & Equity	9,350	11,659	13,403	15,647	21,128	21,037	22,861	23,963	23,663	25,152	27,101	29,463	32,718	37,387	42,496

Cash Flow

Abridged

Understanding Cash Flow Statement

Cipla Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2012 Mar 31	C 2013 Mar 31	2014 Mar 31	2015 Mar 31	R 2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR
Operating CF bef Changes in Working Cap	1,487	1,978	2,096	1,757	2,018	2,004	2,161	2,668	2,582	3,325	3,475	3,846	5,083	5,894	4,351
Working Capital - Increase/(Decrease)	245	-520	-562	-719	-429	231	-783	-1,064	373	372	-177	-559	-806	-665	-225
Net CF from Operating Activities	1,733	1,459	1,534	1,038	1,589	2,235	1,378	1,605	2,955	3,697	3,297	3,287	4,277	5,229	4,126
Capital Expenditures - Net	557	752	567	626	1,053	1,098	739	504	986	791	666	1,134	1,315	1,504	2,986
Net CF from Investing Activities	-1,009	-2,157	-1,343	-973	-4,532	-1,325	-887	-1,741	54	-2,449	-1,919	-2,503	-3,196	-3,951	-2,549
Dividends Paid - Cash - Total	161	161	161	161	161	161	161	242	564	-	403	404	686	1,050	1,292
Stock - Issuance/(Retirement) - Net	-	-	-	0	3	12	0	0	22	-36	-3	0	0	0	0
Debt - LT & ST - Issuance/(Retirement) - Total	-543	938	43	508	3,442	-1,080	-34	-60	-1,760	-1,168	-1,098	-486	-377	-166	80
Net Cash Flow from Financing Activities	-729	751	-145	332	3,265	-1,164	-268	-190	-2,785	-1,209	-1,524	-893	-1,136	-1,256	-1,197
Free Cash Flow to Equity	633	1,644	1,011	920	3,978	57	604	1,041	209	1,737	1,533	1,667	2,585	3,559	1,220
Free Operating CF net dividend	1,011	541	804	231	351	938	401	836	1,391	2,878	2,193	1,700	2,242	2,631	-246
Free Operating CF	1,172	702	965	392	512	1,099	562	1,078	1,955	2,878	2,596	2,104	2,928	3,681	1,047

Business Segment Analysis

FY End:

Mar 26

Cipla Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Pharmaceuticals (100.0%)₹ 3,079.31 Cr

Revenue / Sales

Pharmaceuticals (100.0%)₹ 28,162.59 Cr

Assets

Pharmaceuticals (100.0%)₹ 42,495.98 Cr

Operating Income

Pharmaceuticals (100.0%)₹ 4,841.30 Cr

Regional Segment Analysis

FY End:

Mar 26

Cipla Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

India (45.0%)₹ 12,680.26 CrUnited States (24.4%)₹ 6,871.50 CrRest of the World (15.4%)₹ 4,325.38 CrSouth Africa (15.2%)₹ 4,285.45 Cr

Historical Segment Analysis

Track how Cipla Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2026 Mar 31

Pharmaceuticals	3,079

Frequently Asked Questions

What is the revenue of Cipla Ltd.?

The latest trailing twelve month revenue of Cipla Ltd. is ₹ 28,162.60 Cr, reflecting a 1-year growth of 2.23% and a 3-year CAGR of 7.37%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Cipla Ltd.?

The latest trailing twelve month net profit (PAT) of Cipla Ltd. is ₹ 3,879.23 Cr, with a 3-year earnings CAGR of 11.45%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Cipla Ltd.?

The trailing twelve month EBITDA of Cipla Ltd. is approximately ₹ 4,713.94 Cr (based on an operating margin of 16.74%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Cipla Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Cipla Ltd. is 48.03. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Cipla Ltd.?

The debt-to-equity ratio of Cipla Ltd. stands at 0.02. The interest coverage ratio is 86.67x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Cipla Ltd.?

The estimated book value per share of Cipla Ltd. is 427.19 (derived from a P/B ratio of 3.42 and market price of ₹ 1,459.30), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Cipla Ltd.?

The trailing twelve month operating cash flow of Cipla Ltd. is ₹ 4,125.91 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Cipla Ltd. report consolidated or standalone financials?

Cipla Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.